Management of severe heart failure.

Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF). In therapy for new-onset acute HF associated with acute myocardial infarction, therapy to inhibit left ventricular (LV) remodeling in the convalescent phase is required in addition to that needed to overcome the acute phase. Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart. Most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic; an angiotensin converting enzyme inhibitor and/or an angiotensin II receptor blocker; and a beta-blocker. The administration of beta-blockers is of particular importance. For HF unresponsive to medical therapy, non-pharmacological therapies are considered. When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary. Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants. 11 cases were indicated for heart transplantation but died before registration. It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.

[1]  Kiyoshi Yoshida,et al.  Elevated E/E' predicts prognosis in congestive heart failure patients with preserved systolic function. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[2]  T. Yoshikawa,et al.  Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[3]  Y. Okutani,et al.  Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Jeroen J. Bax,et al.  Results of the Predictors of Response to CRT (PROSPECT) Trial , 2008, Circulation.

[5]  I. Takeuchi,et al.  Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[6]  P. Armstrong,et al.  Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia , 2008, Circulation.

[7]  A. Hirayama,et al.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2007, The Lancet.

[8]  M. Kodama,et al.  Characterization of outpatients with isolated diastolic dysfunction and evaluation of the burden in a Japanese community: Sado Heart Failure Study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[9]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2007, Journal of the American College of Cardiology.

[10]  G. Filippatos,et al.  Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. , 2006, The American journal of medicine.

[11]  Eric Boersma,et al.  Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. , 2006, European heart journal.

[12]  J. Rouleau,et al.  Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.

[13]  P. Ponikowski,et al.  Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia , 2006 .

[14]  S. Ricksten,et al.  Recombinant human atrial natriuretic peptide in ischemic acute renal failure: A randomized placebo-controlled trial* , 2004, Critical care medicine.

[15]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[16]  D. Silverberg,et al.  The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. , 2003, Clinical nephrology.

[17]  A. Takeshita,et al.  Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. , 2001, The American journal of cardiology.

[18]  S. Ogawa,et al.  Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. , 2000, The American journal of cardiology.

[19]  D. DeMets,et al.  A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. , 1999, The New England journal of medicine.

[20]  J T Watson,et al.  The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. , 1999, The Annals of thoracic surgery.

[21]  J. Almeida Intermediate-term outcome of mitral reconstruction in cardiomyopathy. , 1999, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[22]  D. DeMets,et al.  A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure , 1998 .

[23]  H. Krum,et al.  Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy , 1998 .

[24]  A. Skene,et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.

[25]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[26]  H. Imura,et al.  Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. , 1987, Circulation.

[27]  B. Gersh Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2008 .

[28]  W. Frishman,et al.  Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure , 2007 .